重组尿激酶原溶栓治疗急性心肌梗死疗效观察

目的 观察尿激酶原(Pro-uk)溶栓治疗急性心肌梗死(AMI)的疗效及安全性.方法 随机选择2004.05-2005.05间于内蒙古医学院第一附属医院住院的68例发病6 h内的AMI患者,分为Pro-uk组(n=43)和尿激酶(UK)组(n=25).其中Pro-uk 50 mg组22例、Pro-uk 60 mg组21例.在溶栓90 min时进行选择性冠状动脉造影,评价梗死相关动脉开通情况,评价早期心脏事件发生率、出血并发症以及不良反应发生率.结果 ①Pm-uk组总的梗死相关动脉再通率(TIMl2级+TIMl3级)为76.7%,明显高于UK组52.2%(P=0.041).②Pro-uk组轻度出血并发症显著低于UK组(P=0.029);两组均无颅内出血等严重并发症发生.③早期心脏事件发生率以及不良反应发生率两组差异均无统汁学意义.结论 Pro-uk静脉溶栓治疗AMI安全有效.

Therapeutic effects of recombinant prourokinase on patients with acute myocardical infarction

Objective To investigate the therapeutic effect and side effect of prourokinase (Pro-uk) on the patients with acute myocardial infarction. Method From May 2004 to May 2005, a total of 68 cases of acute myocardial infarction treated by thrombolytic agents within 6 hours after onset were divided randomly into Pro-uk group ( n = 43) and urokinase (UK) group ( re = 25). In the Pro- uk group, there were 22 eases treated with 50 mg Pro-uk and 21 cases prescribed in 60 mg Pro-uk. The patency of involved coronary artery was evaluated by using selective coronary angiography at 90 minutes after thrombolytic therapy. The incidence of early heart events, bleeding and adverse reaction, were alse observed. Results (1) The total rates of resumed patency of obstructed coronary artery (TIMI grade 2 and 3 flow) were 76.7% in Pro-uk treated patients and 52.2% in UK treated patient ( P = 0. 041). (2) The occurrence of hyporrhea was lowered more significantly in Pro-uk treated patients than in UK treated patients (P = 0.029), but there were no intracranial hemorrhage found in both group. (3) Early cardiac events and adverse reactions were similar between two groups. Conclusions Pro-UK is safe and effective for the patients with acute myocardial infarction.